Last 12 months
Inside the activity.
0 purchase rows · 27 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 7 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 10 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2017 Filed Apr 21, 2017 20:32 UTC |
Kulkarni SamarthChief Business Officer
|
Exercise / conversionCommon Shares | 2,800 | $1.81 | $5,068.00 |
DisclosureSEC source: 0000899243-17-010731 · doc4.xml · nonDerivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2017 Filed Apr 21, 2017 20:31 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 2,937 | $17.37 | $51,025.09 |
DisclosureSEC source: 0000899243-17-010730 · doc4.xml · nonDerivative · entry 3 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,027 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.11 to $17.59, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:35 UTC |
Novak RodgerDirector · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 47,706 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-010733 · doc4.xml · derivative · entry 6 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,387 Underlying: Common Shares · 47,706 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:35 UTC |
Novak RodgerDirector · Chief Executive Officer
|
SaleCommon Shares | 15,368 | $18.61 | $285,987.72 |
DisclosureSEC source: 0000899243-17-010733 · doc4.xml · nonDerivative · entry 3 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.06 to $19.05, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:35 UTC |
Novak RodgerDirector · Chief Executive Officer
|
SaleCommon Shares | 32,338 | $17.57 | $568,078.41 |
DisclosureSEC source: 0000899243-17-010733 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,230,373 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.05 to $18.045, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:35 UTC |
Novak RodgerDirector · Chief Executive Officer
|
Exercise / conversionCommon Shares | 47,706 | $1.81 | $86,347.86 |
DisclosureSEC source: 0000899243-17-010733 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,262,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:32 UTC |
Kulkarni SamarthChief Business Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 7,258 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-010731 · doc4.xml · derivative · entry 6 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,454 Underlying: Common Shares · 7,258 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:32 UTC |
Kulkarni SamarthChief Business Officer
|
SaleCommon Shares | 2,449 | $18.54 | $45,392.95 |
DisclosureSEC source: 0000899243-17-010731 · doc4.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,047 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05 to $18.99, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:32 UTC |
Kulkarni SamarthChief Business Officer
|
SaleCommon Shares | 4,809 | $17.54 | $84,361.40 |
DisclosureSEC source: 0000899243-17-010731 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,496 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.05 to $18.04, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:32 UTC |
Kulkarni SamarthChief Business Officer
|
Exercise / conversionCommon Shares | 7,258 | $1.81 | $13,136.98 |
DisclosureSEC source: 0000899243-17-010731 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:31 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 2,310 | $18.58 | $42,915.64 |
DisclosureSEC source: 0000899243-17-010730 · doc4.xml · nonDerivative · entry 2 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,964 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.12 to $18.99, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:31 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 4,930 | $17.49 | $86,249.36 |
DisclosureSEC source: 0000899243-17-010730 · doc4.xml · nonDerivative · entry 1 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,274 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.05 to $17.80, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 24, 2016 Filed Oct 24, 2016 18:58 UTC | ConversionSeries B Convertible Preferred Shares · Derivative | 744,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-16-151611 · a4.xml · derivative · entry 2 Hadley Harbor Master Investors (Cayman) L.P. · CIK 0001641080 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 744,380 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Convertible Preferred Shares converted into common shares on a one-for-one basis and had no expiration date. F1 · derivative.exercise_date: The Series B Convertible Preferred Shares converted into common shares on a one-for-one basis and had no expiration date. F1 · derivative.expiration_date: The Series B Convertible Preferred Shares converted into common shares on a one-for-one basis and had no expiration date. Read SEC document |
|
| October 24, 2016 Filed Oct 24, 2016 18:58 UTC | ConversionCommon Shares | 744,380 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-151611 · a4.xml · nonDerivative · entry 1 Hadley Harbor Master Investors (Cayman) L.P. · CIK 0001641080 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 744,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B Convertible Preferred Shares converted into common shares on a one-for-one basis and had no expiration date. Read SEC document |
|
| October 24, 2016 Filed Oct 26, 2016 16:15 UTC |
CELGENE CORP /DE/10% owner
|
ConversionSeries B Preferred Shares · Derivative | 4,034,830 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146978 · doc4.xml · derivative · entry 3 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 4,034,830 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F1 · price: These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F4 · derivative.expiration_date: These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date. F2 · ownership.direct: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.direct: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 16:15 UTC |
CELGENE CORP /DE/10% owner
|
PurchaseCommon Stock | 800,150 | $14.00 | $11,202,100.00 |
DisclosureSEC source: 0001209191-16-146978 · doc4.xml · nonDerivative · entry 2 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,834,980 F2 · ownership.direct: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.direct: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 16:15 UTC |
CELGENE CORP /DE/10% owner
|
ConversionCommon Stock | 4,034,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146978 · doc4.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,034,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.direct: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 21:49 UTC |
GSK plc10% owner
|
ConversionSeries B Preferred Shares · Derivative | 211,567 | $0.00 | $0.00 |
DisclosureSEC source: 0000903423-16-001320 · glaxo-crispr.xml · derivative · entry 5 GLAXOSMITHKLINE PLC · CIK 0001131399 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 0 Underlying: Common Shares · 211,567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On October 24, 2016, the Series A-3 Preferred Shares and the Series B Preferred Shares converted automatically into Common Shares on a one-for-one basis, upon closing of the Issuer's initial public offering F3 · derivative.exercise_date: On October 24, 2016, the Series A-3 Preferred Shares and the Series B Preferred Shares converted automatically into Common Shares on a one-for-one basis, upon closing of the Issuer's initial public offering F4 · derivative.expiration_date: Not applicable. F2 · ownership.nature: The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person"). Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 21:49 UTC |
GSK plc10% owner
|
ConversionSeries A-3 Preferred Shares · Derivative | 2,942,560 | $0.00 | $0.00 |
DisclosureSEC source: 0000903423-16-001320 · glaxo-crispr.xml · derivative · entry 4 GLAXOSMITHKLINE PLC · CIK 0001131399 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 0 Underlying: Common Shares · 2,942,560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On October 24, 2016, the Series A-3 Preferred Shares and the Series B Preferred Shares converted automatically into Common Shares on a one-for-one basis, upon closing of the Issuer's initial public offering F3 · derivative.exercise_date: On October 24, 2016, the Series A-3 Preferred Shares and the Series B Preferred Shares converted automatically into Common Shares on a one-for-one basis, upon closing of the Issuer's initial public offering F4 · derivative.expiration_date: Not applicable. F2 · ownership.nature: The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person"). Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 21:49 UTC |
GSK plc10% owner
|
PurchaseCommon Shares | 66,500 | $14.00 | $931,000.00 |
DisclosureSEC source: 0000903423-16-001320 · glaxo-crispr.xml · nonDerivative · entry 3 GLAXOSMITHKLINE PLC · CIK 0001131399 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 3,220,627 F1 · kind: On October 24, 2016, S.R. One, Limited ("S.R. One") acquired 66,500 common shares of the Issuer ("Common Shares") at a price of $14.00 per share in connection with the Issuer's initial public offering. F1 · price: On October 24, 2016, S.R. One, Limited ("S.R. One") acquired 66,500 common shares of the Issuer ("Common Shares") at a price of $14.00 per share in connection with the Issuer's initial public offering. F2 · ownership.nature: The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person"). Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 21:49 UTC |
GSK plc10% owner
|
ConversionCommon Shares | 211,567 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000903423-16-001320 · glaxo-crispr.xml · nonDerivative · entry 2 GLAXOSMITHKLINE PLC · CIK 0001131399 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 3,154,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: On October 24, 2016, the Series A-3 Preferred Shares and the Series B Preferred Shares converted automatically into Common Shares on a one-for-one basis, upon closing of the Issuer's initial public offering F2 · ownership.nature: The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person"). Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 21:49 UTC |
GSK plc10% owner
|
ConversionCommon Shares | 2,942,560 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000903423-16-001320 · glaxo-crispr.xml · nonDerivative · entry 1 GLAXOSMITHKLINE PLC · CIK 0001131399 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 2,942,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: On October 24, 2016, the Series A-3 Preferred Shares and the Series B Preferred Shares converted automatically into Common Shares on a one-for-one basis, upon closing of the Issuer's initial public offering F2 · ownership.nature: The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person"). Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 22:28 UTC |
COLES N ANTHONYDirector
|
GrantCommon Stock | 35,000 | $14.00 | $490,000.00 |
DisclosureSEC source: 0000899243-16-032310 · doc4.xml · nonDerivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Coles Family Trust Disclosed balance after: 70,000 Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 22:28 UTC |
COLES N ANTHONYDirector
|
GrantCommon Stock | 35,000 | $14.00 | $490,000.00 |
DisclosureSEC source: 0000899243-16-032310 · doc4.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 70,000 Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 22:28 UTC |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Venture Capital V, L.P.10% owner
|
GrantCommon Stock | 4,583 | $14.00 | $64,162.00 |
DisclosureSEC source: 0000899243-16-032308 · doc4.xml · nonDerivative · entry 4 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 185,987 F4 · ownership.nature: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V CAN GP and share voting and dispositive power over the shares held by VVC CAN; however, they each disclaim beneficial ownership of the shares held by VVC CAN, except to the extent of their pecuniary interests therein. F5 · ownership.nature: This report on Form 4 is jointly filed by VVC IV, VSF IV, VVC V and VVC CAN. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 22:28 UTC |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Venture Capital V, L.P.10% owner
|
GrantCommon Stock | 60,219 | $14.00 | $843,066.00 |
DisclosureSEC source: 0000899243-16-032308 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,443,803 F3 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VVC V; however, they each disclaim beneficial ownership of the shares held by VVC V, except to the extent of their pecuniary interests therein. F5 · ownership.nature: This report on Form 4 is jointly filed by VVC IV, VSF IV, VVC V and VVC CAN. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 22:28 UTC |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Venture Capital V, L.P.10% owner
|
GrantCommon Stock | 602 | $14.00 | $8,428.00 |
DisclosureSEC source: 0000899243-16-032308 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 24,334 F2 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. Brian G. Atwood, Samuel D. Colella, Ross A. Jaffe, William J. Link, Rebecca B. Robertson, Bradley Bolzon, Ph.D., Charles M. Warden, Kirk G. Nielsen, Thomas Woiwode and Robin L. Praeger are managing directors of VV IV and share voting and dispositive power over the shares held by VSF IV; however, they each disclaim beneficial ownership of the shares held by VVC IV and VSF IV, except to the extent of their pecuniary interests therein. F5 · ownership.nature: This report on Form 4 is jointly filed by VVC IV, VSF IV, VVC V and VVC CAN. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 22:28 UTC |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Venture Capital V, L.P.10% owner
|
GrantCommon Stock | 95,596 | $14.00 | $1,338,344.00 |
DisclosureSEC source: 0000899243-16-032308 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,104,045 F1 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. Brian G. Atwood, Samuel D. Colella, Ross A. Jaffe, William J. Link, Rebecca B. Robertson, Bradley Bolzon, Ph.D., Charles M. Warden, Kirk G. Nielsen, Thomas Woiwode and Robin L. Praeger are managing directors of VV IV and share voting and dispositive power over the shares held by VVC IV; however, they each disclaim beneficial ownership of the shares held by VVC IV and VSF IV, except to the extent of their pecuniary interests therein. F5 · ownership.nature: This report on Form 4 is jointly filed by VVC IV, VSF IV, VVC V and VVC CAN. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 21:51 UTC |
George SimeonDirector
|
ConversionSeries B Preferred Shares · Derivative | 211,567 | $0.00 | $0.00 |
DisclosureSEC source: 0000903423-16-001321 · george-crispr.xml · derivative · entry 5 George Simeon · CIK 0001595117 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 0 Underlying: Common Shares · 211,567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On October 24, 2016, the Series A-3 Preferred Shares and the Series B Preferred Shares converted automatically into Common Shares on a one-for-one basis, upon closing of the Issuer's initial public offering F3 · derivative.exercise_date: On October 24, 2016, the Series A-3 Preferred Shares and the Series B Preferred Shares converted automatically into Common Shares on a one-for-one basis, upon closing of the Issuer's initial public offering F4 · derivative.expiration_date: Not applicable. F2 · ownership.nature: These shares are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Simeon J. George (the "Reporting Person") is a Vice President at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. The Reporting Person disclaims beneficial ownership of all the shares herein and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his proportionate pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 21:51 UTC |
George SimeonDirector
|
ConversionSeries A-3 Preferred Shares · Derivative | 2,942,560 | $0.00 | $0.00 |
DisclosureSEC source: 0000903423-16-001321 · george-crispr.xml · derivative · entry 4 George Simeon · CIK 0001595117 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 0 Underlying: Common Shares · 2,942,560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On October 24, 2016, the Series A-3 Preferred Shares and the Series B Preferred Shares converted automatically into Common Shares on a one-for-one basis, upon closing of the Issuer's initial public offering F3 · derivative.exercise_date: On October 24, 2016, the Series A-3 Preferred Shares and the Series B Preferred Shares converted automatically into Common Shares on a one-for-one basis, upon closing of the Issuer's initial public offering F4 · derivative.expiration_date: Not applicable. F2 · ownership.nature: These shares are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Simeon J. George (the "Reporting Person") is a Vice President at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. The Reporting Person disclaims beneficial ownership of all the shares herein and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his proportionate pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 21:51 UTC |
George SimeonDirector
|
PurchaseCommon Shares | 66,500 | $14.00 | $931,000.00 |
DisclosureSEC source: 0000903423-16-001321 · george-crispr.xml · nonDerivative · entry 3 George Simeon · CIK 0001595117 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 3,220,627 F1 · kind: On October 24, 2016, S.R. One, Limited ("S.R. One") acquired 66,500 common shares of the Issuer ("Common Shares") at a price of $14.00 per share in connection with the Issuer's initial public offering. F1 · price: On October 24, 2016, S.R. One, Limited ("S.R. One") acquired 66,500 common shares of the Issuer ("Common Shares") at a price of $14.00 per share in connection with the Issuer's initial public offering. F2 · ownership.nature: These shares are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Simeon J. George (the "Reporting Person") is a Vice President at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. The Reporting Person disclaims beneficial ownership of all the shares herein and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his proportionate pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 21:51 UTC |
George SimeonDirector
|
ConversionCommon Shares | 211,567 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000903423-16-001321 · george-crispr.xml · nonDerivative · entry 2 George Simeon · CIK 0001595117 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 3,154,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: On October 24, 2016, the Series A-3 Preferred Shares and the Series B Preferred Shares converted automatically into Common Shares on a one-for-one basis, upon closing of the Issuer's initial public offering F2 · ownership.nature: These shares are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Simeon J. George (the "Reporting Person") is a Vice President at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. The Reporting Person disclaims beneficial ownership of all the shares herein and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his proportionate pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 21:51 UTC |
George SimeonDirector
|
ConversionCommon Shares | 2,942,560 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000903423-16-001321 · george-crispr.xml · nonDerivative · entry 1 George Simeon · CIK 0001595117 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 2,942,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: On October 24, 2016, the Series A-3 Preferred Shares and the Series B Preferred Shares converted automatically into Common Shares on a one-for-one basis, upon closing of the Issuer's initial public offering F2 · ownership.nature: These shares are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Simeon J. George (the "Reporting Person") is a Vice President at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. The Reporting Person disclaims beneficial ownership of all the shares herein and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his proportionate pecuniary interest therein, if any. Read SEC document |
| October 24, 2016 Filed Oct 27, 2016 16:45 UTC Amendment |
CELGENE CORP /DE/10% owner
|
ConversionSeries B Preferred Shares · Derivative | 4,034,830 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-147161 · doc4a.xml · derivative · entry 3 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 0 Underlying: Common Shares · 4,034,830 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F1 · price: These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F4 · derivative.expiration_date: These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date. F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document |
| October 24, 2016 Filed Oct 27, 2016 16:45 UTC Amendment |
CELGENE CORP /DE/10% owner
|
PurchaseCommon Stock | 800,150 | $14.00 | $11,202,100.00 |
DisclosureSEC source: 0001209191-16-147161 · doc4a.xml · nonDerivative · entry 2 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 4,834,980 F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document |
| October 24, 2016 Filed Oct 27, 2016 16:45 UTC Amendment |
CELGENE CORP /DE/10% owner
|
ConversionCommon Stock | 4,034,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-147161 · doc4a.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 4,034,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Venture Capital V, L.P.10% owner
Versant Affiliates Fund V, L.P.10% owner
|
ConversionSeries B Preferred Shares · Derivative | 5,774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 32 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 5,774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F7 · ownership.nature: These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Venture Capital V, L.P.10% owner
Versant Affiliates Fund V, L.P.10% owner
|
ConversionSeries B Preferred Shares · Derivative | 13,180 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 31 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 13,180 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F6 · ownership.nature: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Venture Capital V, L.P.10% owner
Versant Affiliates Fund V, L.P.10% owner
|
ConversionSeries B Preferred Shares · Derivative | 5,210 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 30 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 5,210 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F5 · ownership.nature: These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Venture Capital V, L.P.10% owner
Versant Affiliates Fund V, L.P.10% owner
|
ConversionSeries B Preferred Shares · Derivative | 173,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 29 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 173,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F4 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Venture Capital V, L.P.10% owner
Versant Affiliates Fund V, L.P.10% owner
|
ConversionSeries B Preferred Shares · Derivative | 1,454 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 28 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,454 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F3 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Venture Capital V, L.P.10% owner
Versant Affiliates Fund V, L.P.10% owner
|
ConversionSeries B Preferred Shares · Derivative | 231,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 27 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 231,077 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Venture Capital V, L.P.10% owner
Versant Affiliates Fund V, L.P.10% owner
|
ConversionSeries A-3 Preferred Shares · Derivative | 73,704 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 26 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 73,704 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F7 · ownership.nature: These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Venture Capital V, L.P.10% owner
Versant Affiliates Fund V, L.P.10% owner
|
ConversionSeries A-3 Preferred Shares · Derivative | 168,224 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 25 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 168,224 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F6 · ownership.nature: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Venture Capital V, L.P.10% owner
Versant Affiliates Fund V, L.P.10% owner
|
ConversionSeries A-3 Preferred Shares · Derivative | 66,490 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 24 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 66,490 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F5 · ownership.nature: These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Venture Capital V, L.P.10% owner
Versant Affiliates Fund V, L.P.10% owner
|
ConversionSeries A-3 Preferred Shares · Derivative | 2,210,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 23 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,210,417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F4 · ownership.nature: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Venture Capital V, L.P.10% owner
Versant Affiliates Fund V, L.P.10% owner
|
ConversionSeries A-2 Preferred Shares · Derivative | 19,524 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 22 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 19,524 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F3 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Venture Capital V, L.P.10% owner
Versant Affiliates Fund V, L.P.10% owner
|
ConversionSeries A-2 Preferred Shares · Derivative | 3,100,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 21 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,100,477 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Venture Capital V, L.P.10% owner
Versant Affiliates Fund V, L.P.10% owner
|
ConversionSeries A-1 Preferred Shares · Derivative | 2,754 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 20 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,754 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F3 · ownership.nature: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interests therein. Read SEC document |
| October 24, 2016 Filed Dec 23, 2016 23:03 UTC Amendment |
Versant Venture Capital IV, L.P.10% owner
Versant Side Fund IV, L.P.10% owner
Versant Venture Capital V, L.P.10% owner
Versant Affiliates Fund V, L.P.10% owner
|
ConversionSeries A-1 Preferred Shares · Derivative | 437,247 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-163806 · a4a.xml · derivative · entry 19 Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 437,247 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016. F2 · ownership.nature: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.